
NMRA Stock Forecast & Price Target
NMRA Analyst Ratings
Bulls say
Neumora Therapeutics Inc. is positioned for strong growth, with projected U.S. sales reaching $250 million by 2030 and $950 million by 2035, aligning with market consensus. Its lead asset, Navacaprant, is anticipated to be successful in its Phase 3 program for Major Depressive Disorder (MDD), with a sales potential of $750 million by 2028 and a peak estimate of $3 billion. Additionally, the company’s focus on innovative approaches to underserved neuropsychiatric and neurodegenerative disorders positions it for significant long-term shareholder value.
Bears say
Neumora Therapeutics Inc has faced significant setbacks, notably the failure of the KOASTAL-1 study and the discontinuation of aticaprant development by Johnson & Johnson, which contribute to ongoing concerns regarding the stock's performance. Although management has made changes and there is cautious optimism about the K2/K-3 studies, lack of conviction surrounding their outcomes raises doubts about the company's ability to successfully advance its pipeline. This combination of project failures and uncertainty about future studies creates a challenging environment for investor confidence.
This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares